DURHAM, NC--(Marketwire - April 17, 2008) - Coserics, LLC today announced its formation following a successful spin-out from Serenex, Inc. The new company commences operations with a clinical stage compound, SNX-1012, that is in phase 2 testing for treatment of chemotherapy induced oral mucositis in solid tumor patients.
